Needham & Company LLC reissued their buy rating on shares of NextCure (NASDAQ:NXTC – Free Report) in a report issued on Friday, Benzinga reports. Needham & Company LLC currently has a $4.00 target price on the stock.
Separately, HC Wainwright restated a buy rating and issued a $8.00 target price on shares of NextCure in a report on Friday, May 31st.
Check Out Our Latest Analysis on NXTC
NextCure Price Performance
NextCure (NASDAQ:NXTC – Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.19). On average, equities analysts forecast that NextCure will post -1.71 earnings per share for the current year.
Institutional Trading of NextCure
Several institutional investors have recently made changes to their positions in NXTC. Affinity Asset Advisors LLC purchased a new stake in NextCure in the 1st quarter worth approximately $3,031,000. Cable Car Capital LLC purchased a new stake in shares of NextCure during the fourth quarter worth $702,000. Assenagon Asset Management S.A. purchased a new stake in shares of NextCure during the first quarter worth $952,000. Acuitas Investments LLC grew its stake in NextCure by 30.0% in the fourth quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock valued at $425,000 after purchasing an additional 85,982 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in NextCure by 9.3% in the first quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock valued at $2,202,000 after purchasing an additional 83,700 shares in the last quarter. 42.65% of the stock is currently owned by institutional investors and hedge funds.
About NextCure
NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.
Further Reading
- Five stocks we like better than NextCure
- Election Stocks: How Elections Affect the Stock Market
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- What is the Shanghai Stock Exchange Composite Index?
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
- What are earnings reports?
- Why Warren Buffett Just Sold Half His Stake in Apple Stock
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.